1–1 of 1 result for Ref-1 inhibition
ZETA-1 Phase 2 Trial Efficacy Results for APX3330 a Novel Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy
David R Lally, MD
Annual Meeting Talks
2023